Summit Therapeutics Plc Stock Return On Asset
| SMMT Stock | USD 19.44 0.67 3.33% |
Summit Therapeutics PLC fundamentals help investors to digest information that contributes to Summit Therapeutics' financial success or failures. It also enables traders to predict the movement of Summit Stock. The fundamental analysis module provides a way to measure Summit Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Summit Therapeutics stock.
Summit |
Summit Therapeutics PLC Company Return On Asset Analysis
Summit Therapeutics' Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Current Summit Therapeutics Return On Asset | -0.41 |
Most of Summit Therapeutics' fundamental indicators, such as Return On Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Summit Therapeutics PLC is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
| Competition |
Based on the latest financial disclosure, Summit Therapeutics PLC has a Return On Asset of -0.4131. This is 95.28% lower than that of the Biotechnology sector and 98.25% lower than that of the Health Care industry. The return on asset for all United States stocks is 195.07% higher than that of the company.
Summit Return On Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Summit Therapeutics' direct or indirect competition against its Return On Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Summit Therapeutics could also be used in its relative valuation, which is a method of valuing Summit Therapeutics by comparing valuation metrics of similar companies.Summit Therapeutics is currently under evaluation in return on asset category among its peers.
Summit Fundamentals
| Return On Equity | -0.95 | ||||
| Return On Asset | -0.41 | ||||
| Current Valuation | 14.43 B | ||||
| Shares Outstanding | 737.68 M | ||||
| Shares Owned By Insiders | 84.36 % | ||||
| Shares Owned By Institutions | 12.91 % | ||||
| Number Of Shares Shorted | 21.45 M | ||||
| Price To Earning | 2.85 X | ||||
| Price To Book | 38.16 X | ||||
| Price To Sales | 753.90 X | ||||
| Gross Profit | 705 K | ||||
| EBITDA | 313 K | ||||
| Net Income | (221.31 M) | ||||
| Cash And Equivalents | 121.97 M | ||||
| Cash Per Share | 0.61 X | ||||
| Total Debt | 7.22 M | ||||
| Debt To Equity | 0.03 % | ||||
| Current Ratio | 8.22 X | ||||
| Book Value Per Share | 0.53 X | ||||
| Cash Flow From Operations | (142.11 M) | ||||
| Short Ratio | 9.05 X | ||||
| Earnings Per Share | (0.31) X | ||||
| Target Price | 34.85 | ||||
| Number Of Employees | 159 | ||||
| Beta | -1.04 | ||||
| Market Capitalization | 14.83 B | ||||
| Total Asset | 435.56 M | ||||
| Retained Earnings | (1.21 B) | ||||
| Working Capital | 382.02 M | ||||
| Current Asset | 20.86 M | ||||
| Current Liabilities | 3.21 M | ||||
| Net Asset | 435.56 M |
About Summit Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Summit Therapeutics PLC's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Summit Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Summit Therapeutics PLC based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Summit Stock Analysis
When running Summit Therapeutics' price analysis, check to measure Summit Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Summit Therapeutics is operating at the current time. Most of Summit Therapeutics' value examination focuses on studying past and present price action to predict the probability of Summit Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Summit Therapeutics' price. Additionally, you may evaluate how the addition of Summit Therapeutics to your portfolios can decrease your overall portfolio volatility.